Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
70.13
-3.47 (-4.71%)
At close: Apr 28, 2026, 4:00 PM EDT
70.49
+0.36 (0.52%)
After-hours: Apr 28, 2026, 4:21 PM EDT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $264.03M in the quarter ending December 31, 2025, with 10,461.32% growth. This brings the company's revenue in the last twelve months to $1.09B, up 43,539.24% year-over-year. In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M with 23,258.15% growth.
Revenue (ttm)
$1.09B
Revenue Growth
+43,539.24%
P/S Ratio
9.27
Revenue / Employee
$1,534,432
Employees
711
Market Cap
9.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | Pro | Pro | Pro |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Bio-Techne | 1.22B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
| Axsome Therapeutics | 638.50M |
| Praxis Precision Medicines | 7.46M |
ARWR News
- 4 days ago - Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe - Business Wire
- 7 days ago - This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. - Barrons
- 8 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Arrowhead Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts